Navigation Links
Genomic Health to Announce Second Quarter 2012 Financial Results and Host Conference Call on Wednesday, August 8, 2012
Date:8/1/2012

t cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS).  In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease.  As of March 31, 2012, more than 10,000 physicians in over 65 countries had ordered more than 275,000 Oncotype DX tests.  Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional treatment decisions in breast and colon cancers.  The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.  For more information, please visit, www.GenomicHealth.com. To learn more about Oncotype DX tests, visit: www.OncotypeDX.com and www.mybreastcancertreatment.org.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes and focus of the company's product pipeline, the ability of the company to develop additional tests in the future, and the ability of any potential tests the company may develop to optimize cancer treatment. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be consider
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Elsevier Launches New Open Access Journal: Applied and Translational Genomics
2. Life Technologies Acquires Pinpoint Genomics and CLIA-Approved Lung Cancer Test
3. Life Technologies Signs Collaborative Agreement with Structural Genomics Consortium to Develop First Antibody Master Set for Epigenetic Studies
4. Gentris Corporation Launches New Pharmacogenomics Services
5. Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications
6. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
7. Genomic Health to Announce First Quarter 2012 Financial Results and Host Conference Call on Wednesday, May 2, 2012
8. Empire Genomics Chooses Funakoshi as Japan Distributor
9. Save Up To 25% on International Biotech and Healthcare, and Pharmaceutical Conferences by Registering Through GII
10. Independa, IDEAL LIFE to Provide Plug-and-Play Health Monitoring for Independent Elderly and Their Caregivers
11. GHX WebConnect Fuels Healthcare Efficiency at 2012 Olympics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... 7, 2011 In an address to ... John C. Lechleiter, Ph.D., chairman, president and chief executive ... build a new level of trust between the biopharmaceutical ... can harness innovation to help meet growing health care ...
... 2011 Merit Medical Systems, Inc. (NASDAQ: MMSI ... used primarily in cardiology, radiology and endoscopy, announced today that ... quarter ended June 30, 2011, after the close of the ... will hold its investor conference call on the same day ...
Cached Medicine Technology:Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 2Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 3Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 4
(Date:7/10/2014)... Harbor, NY For decades, health-conscious people around the ... in antioxidants, figuring this was one of the paths ... , Yet clinical trials of antioxidant supplements have repeatedly ... to reduce their cancer risk. Virtually all such ... cancer. In fact, in several trials antioxidant supplementation ...
(Date:7/10/2014)... at sarcomas research group at the Bellvitge Biomedical Research ... have been tested in 19 patients a new therapeutic ... which indicate that the new treatment could stabilize the ... in the British Journal of Cancer ., ... and complex since there are several subtypes. It can ...
(Date:7/10/2014)... a new drug could prove useful in treating small cell ... , Scientists from the Cancer Research UK Manchester Institute, based ... Cancer Research Centre, teamed up with experts at AstraZeneca, as ... drug known as AZD3965 - on small cell lung ... Clinical Cancer Research , also helps identify which patients are ...
(Date:7/9/2014)... WASHINGTON, DC (July 10, 2014) If you think winning ... fun for kids think again: Winning along with other mental ... each of which falls into one of 11 big fun ... that winning is all important when it comes to the ... identify and quantify what goes into this elusive conceptuntil now. ...
(Date:7/9/2014)... of low back pain are not linked to weather ... and precipitation. Findings published in Arthritis Care & ... Rheumatology (ACR), indicate that the risk of low back ... gusts, but was not clinically significant. , According ... low back pain at some point in their life, ...
Breaking Medicine News(10 mins):Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Low back pain? Don't blame the weather 2
... in U.S., Canada, study says , FRIDAY, April 16 ... places across the United States and Canada could save ... die of cardiac arrest each year, researchers report. , ... in more limited setting, such as casinos or airports, ...
... Inserting new valve within the valve might help high-risk ... -- If an artificial heart valve derived from a ... implanting a mechanical valve inside the artificial valve could ... and opened, the new valve opens and functions similarly ...
... brain lesions developed in patients taking Lipitor than placebo, ... Cholesterol-lowering statin drugs may slow the progression of multiple ... 81 patients with early-stage MS randomly selected to take ... a placebo. After 12 months of treatment, 55.3 percent ...
... Cardiovascular disease appears to be a major risk factor ... -- People with atrial fibrillation, a form of abnormal heart ... Alzheimer,s disease, a new study finds. , The presence of ... especially among younger patients in the group studied, meaning under ...
... Mo. For seniors, dancing isn,t just for fun; ... by University of Missouri researchers found that participation in ... adults. Improved functionality among seniors can decrease their risk ... as dance-based therapy have the potential to significantly reduce ...
... ... ... Researchers at Drexel University College of Medicine have discovered that a certain type ... critical for cancer growth and movement. When researchers reduced and normalized the levels of this ...
Cached Medicine News:Health News:Public Defibrillators Save Lives 2Health News:Public Defibrillators Save Lives 3Health News:Cholesterol Drugs May Slow MS 2Health News:Abnormal Heart Rhythm Linked to Alzheimer's 2Health News:Abnormal Heart Rhythm Linked to Alzheimer's 3Health News:Dance therapy improves seniors' gait, balance, researcher finds 2Health News:Scientists Report Key Finding in Breast Cancer Research 2Health News:Scientists Report Key Finding in Breast Cancer Research 3
Non-Illuminated Trial Lens Set is an attractive set of trial lenses worked to a high standard of accuracy....
Trial Lens Sets....
... disc test (P/N LD15C) include a durable ... instructions. P/N LD15C also includes a Plexiglas ... covers for the test subjects fingers ( ... color discs). Beware that these finger cots ...
Opti-Free Express multi-purpose disinfecting solution lasting comfort No Rub formula provides triple action protection for your contact lenses....
Medicine Products: